Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAM10 RNAi
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Intrathecal, Intratumoral, Intraperitoneal, Parenteral, Implant
01
Overview
ADAM10 RNAi refers to RNA interference (RNAi) agents, such as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), designed to target and knock down the expression of A Disintegrin and Metalloproteinase Domain-containing Protein 10 (ADAM10). ADAM10 is a cell surface metalloprotease involved in the proteolytic shedding of various transmembrane proteins, including E-cadherin, CD44, and ligands/receptors of the EGFR and Notch signaling pathways. In preclinical research, ADAM10 RNAi is utilized to investigate the role of ADAM10 in cancer progression, showing that its downregulation inhibits cell proliferation, migration, and invasion in various malignancies, including breast cancer, hepatocellular carcinoma, and hypopharyngeal squamous cell carcinoma.
- Other names
- ADAM10 shRNAADAM-10 shRNAADAM 10 shRNAADAM10 siRNAADAM-10 siRNAADAM 10 siRNAADAM10 small interfering RNAADAM-10 small interfering RNAADAM 10 small interfering RNAshADAM10shADAM-10shADAM 10siADAM10siADAM-10siADAM 10
02
Targets
A disintegrin and metalloproteinase domain-containing protein 10 mRNANOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on ADAM10 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAM10 RNAi.